As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


No evidence alleged Bondi gunmen received military training in Philippines
At least 12 killed in Nigeria mining site attack
Russian attack on Ukraine's central Cherkasy injures six, causes blackouts
UN, aid groups warn Gaza operations at risk from Israel impediments
Israel approves natural gas deal with Egypt, Netanyahu says
US approves $11.1 billion largest-ever arms package for Taiwan
Trump adds seven countries to full travel ban list
Indian parliament votes to allow private firms in nuclear power sector
